Blood-sucking flies help predict outbreaks of infectious disease

A study published in eLife examined the effectiveness in testing blood collected by flies for traces of unknown pathogens, which is improving current predictive methods in global outbreaks.

Methods of predicting the next global outbreak are important ways to save lives before infections travel from animal host to humans. Current methods involve testing animal tissues and organs for the presence of infectious disease. With the number of endangered animals increasing year-by-year, these methods can strain protected species. In response, researchers are studying how using DNA collected by blood-sucking flies can be used as a non-invasive method of infection prediction.

"This is a huge public health issue that urgently requires new tools for the active monitoring of outbreaks and rapid diagnosis of the pathogens involved," explained senior author Franck Prugnolle, an evolutionary geneticist from the National Center for Scientific Research (CNRS) in Montpellier, France. "We wanted to investigate whether blood-feeding insects could act as a sampling tool out in the wild environment, allowing us to monitor the presence and emergence of infectious disease."

Over 16 weeks, researchers collected 4,000 flies from the national parks in Gabon in Central Africa. Three types of flies were collected, 30 percent being the tsetse fly. The blood was tested for host identification and the presence of malaria. Blood was collected from a variety of 20 different animals, including elephants, reptiles and birds. The analyzed samples revealed malaria in 9 percent of blood meals and 18 different undocumented malaria species, while identifying a natural host of the malaria species that was previously unknown.

"These results show that blood meals of the engorged flies can be successfully used to analyze the diversity of known malaria parasites," said Prugnolle. "This approach of 'xenosurveillance' could detect pathogens before they spread to humans, as well as the emergence of new diseases in wild animals that may threaten their long-term survival."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.